---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-036816"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:01:49.130816+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences reports FY 2023 net loss of $61.3M; extends cash runway into H2 2026

## Summary
- FY 2023 revenue $48.7M (up from $25.1M in 2022); loss from continuing ops $42.5M.
- Cash $116.7M at Dec 31, 2023; recent $40M public offering and CAR T licensing deals add ~$50M.
- Completed licensing deals with Imugene, TG Therapeutics, and Caribou; total upfront/near-term ~$50M.
- PBGENE-HBV IND/CTA submission planned in 2024; PBGENE-PMM submission in 2025.
- Net loss per diluted share $(15.96) vs $(38.10) in FY 2022.

## SEC filing metadata
- accession: 0000950170-24-036816
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017024036816/0000950170-24-036816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017024036816/dtil-20240327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-036816
- JSON: https://secwatch.observer/filing/0000950170-24-036816.json
- Plain text: https://secwatch.observer/filing/0000950170-24-036816.txt

## Key facts
- Earnings Releases
  PRECISION BIOSCIENCES INC reported financial results for quarter and fiscal year ended December 31, 2023.
  - Period: quarter and fiscal year ended December 31, 2023
  - Result: reported results
  source text: On March 27, 2024, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357874/000095017024036816/0000950170-24-036816-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.